文献速递膀胱癌与上尿路尿路上皮癌

真实世界对EAU推荐的非肌层浸润性膀胱癌管理的依从性:从循证实践到肿瘤学结局

Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes.
PubMed 文献 · Eur Urol Oncol · 2026-02-19

该回顾性研究分析了六家欧洲三级中心2014-2021年2194例连续接受TURBT的NMIBC患者,评估对EAU指南推荐的早期灌注、二次电切和风险适应膀胱内治疗的依从性及其对肿瘤学结局的影响。结果显示依从性普遍偏低,但依从性与更优的无复发生存和无进展生存相关。

要点

  • 真实世界中EAU推荐的NMIBC管理依从性低:早期灌注22%、二次电切44%、膀胱灌注29%。
  • 依从早期灌注、二次电切和膀胱灌注均与更优的无复发生存相关(HR 0.60、0.53、0.49)。
  • 二次电切和膀胱灌注依从还与更优的无进展生存相关(HR 0.41、0.47)。

核心结论

  • 真实世界实践中对EAU推荐的NMIBC管理依从性仍低,但依从性与更有利的肿瘤学结局相关,应优先通过标准化路径改善指南推荐治疗的实施。

研究设计与样本

  • 回顾性分析六家欧洲三级中心2014-2021年2194例连续接受TURBT的NMIBC患者,采用EAU标准定义早期灌注、二次电切和膀胱内灌注的适用性,通过Sankey图评估依从性,采用Kaplan-Meier分析(逆概率治疗加权)和Cox回归模型比较依从状态下的无复发生存和无进展生存。

主要发现

  • 肿瘤分期分布为63% Ta、32% T1、5.4% Tis;60%为高级别;风险分布为22%低危、27%中危、38%高危、13%极高危。
  • 早期灌注推荐用于1333例患者,实际执行290例(22%);二次电切有指征1006例,实际执行445例(44%);膀胱内灌注推荐1713例,实际启动497例(29%)。
  • 依从早期灌注(79% vs 61%;HR 0.60)、二次电切(70% vs 54%;HR 0.53)和膀胱灌注(72% vs 53%;HR 0.49)与更优的无复发生存相关;二次电切(94% vs 87%;HR 0.41)和膀胱灌注(95% vs 89%;HR 0.47)也改善无进展生存(所有p < 0.001)。

关键数值与推荐

  • 早期灌注推荐用于1333例患者,执行290例(22%)。
  • 二次电切有指征1006例,执行445例(44%)。
  • 膀胱内灌注推荐1713例,启动497例(29%)。
  • 依从早期灌注、二次电切和膀胱灌注与更优无复发生存相关(HR分别为0.60、0.53、0.49,所有p < 0.001)。
  • 依从二次电切和膀胱灌注与更优无进展生存相关(HR分别为0.41、0.47,所有p < 0.001)。

临床怎么用

  • 应优先通过标准化路径改善指南推荐治疗的实施,以提高NMIBC患者的早期灌注、二次电切和膀胱内灌注依从性,从而改善肿瘤学结局。

局限性

  • 未报告不依从的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Adherence to European Association of Urology (EAU) guideline-recommended management of non-muscle-invasive bladder cancer (NMIBC) is essential for optimal outcomes. We quantified real-world adherence to early instillation (EI), second-look transurethral resection of bladder tumor (re-TURBT), and risk-adapted intravesical therapy, and assessed their impact on oncological outcomes. METHODS: We retrospectively analyzed 2194 consecutive NMIBC patients treated with TURBT at six European tertiary centers (2014-2021). Eligibility for EI, re-TURBT, and intravesical instillations was defined using the EAU criteria. Adherence was evaluated through Sankey plots. Recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier analyses with inverse probability of treatment weighting and compared by adherence status. Cox regression models were also fitted. KEY FINDINGS AND LIMITATIONS: Tumor stage distribution was as follows: 63% Ta, 32% T1, and 5.4% Tis stage; 60% were of high grade. Risk distribution was as follows: 22% low, 27% intermediate, 38% high, and 13% very high. EI was recommended in 1333 patients and performed in 290 (22%) patients. Re-TURBT was indicated in 1006 patients and performed in 445 (44%) patients. Intravesical instillations were recommended in 1713 patients and initiated in 497 (29%) patients. Adherence to EI (79% vs 61%; hazard ratio [HR] 0.60), re-TURBT (70% vs 54%; HR 0.53), and instillations (72% vs 53%; HR 0.49) was associated with superior RFS; re-TURBT (94% vs 87%; HR 0.41) and instillations (95% vs 89%; HR 0.47) also improved PFS (all p < 0.001). Nonadherence reasons were not reported. CONCLUSIONS AND CLINICAL IMPLICATIONS: In real-world practice, adherence to EAU-recommended NMIBC management remains low; yet, it is associated with more favorable outcomes. Improving delivery of guideline-based care through standardized pathways should be a priority in NMIBC management.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Longoni M, Scilipoti P, De Angelis M, et al. Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes. Eur Urol Oncol. 2026. PMID: 41720695. doi:10.1016/j.euo.2026.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。